Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189522 | 0.86 | CYP1A2 (0.50) | SCN5ACYP1A2TNFMKNK1MKNK2 | |
| SCHEMBL23572493 | 0.85 | CYP1A2 (0.44) | SCN5ACYP1A2MAP4K4MAP4K1MLYCD | |
| SCHEMBL20209245 | 0.80 | CYP1A2 (0.51) | SCN5ACYP1A2MAP4K4TNFMAP4K1 | |
| SCHEMBL938561 | 0.79 | CYP1A2 (0.65) | SCN5ACYP1A2 | |
| SCHEMBL20209244 | 0.78 | SCN5A (0.55) | SCN5ACYP1A2MAP4K4MAP4K1MLYCD | |
| SCHEMBL20209265 | 0.76 | SCN5A (0.69) | SCN5ATGFBR1 | |
| SCHEMBL26463399 | 0.75 | CYP1A2 (0.44) | CYP1A2MAP4K4TNFMAP4K1MLYCD | |
| SCHEMBL938060 | 0.75 | CYP1A2 (0.60) | SCN5ACYP1A2MAP4K4 | |
| SCHEMBL26462839 | 0.73 | SCN5A (0.44) | SCN5ACYP1A2MAP4K4MAP4K1MLYCD | |
| SCHEMBL938554 | 0.72 | CYP1A2 (0.56) | SCN5ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885MAP4K4 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.